Wild-type ATTR amyloidosis: 2026 so far

Several routine-care analyses reported survival differences between people who did and did not receive tafamidis.

New in the months covered, two large routine-care analyses reported better survival in tafamidis-treated groups compared with similar untreated groups, including a matched comparison in one cohort. These were observational (not randomized), so they cannot prove tafamidis caused the survival difference. Still, they add consistency across different settings. The same real-world work also pointed to gaps in treatment patterns, including lower tafamidis initiation in women in one cohort. This helps put trial results into a routine-care context by showing how outcomes differed between treated and untreated groups, and by highlighting who may be less likely to start therapy in practice.

Research covered in: April 2026, August 2026

Trial analyses went beyond overall scores and looked at specific day-to-day impacts.

In randomized-trial analyses reported so far in 2026, vutrisiran showed modest advantages versus placebo on specific day-to-day symptom and function questionnaire items, especially physical activities (e.g., walking and hurrying/jogging) and feeling discouraged. A separate trial analysis focused on left atrial strain (how well the heart's left upper chamber stretches). Abnormalities were common, they predicted higher risk of death/cardiovascular events, and they worsened more slowly on vutrisiran than placebo over 30 months. These results add detail about what changed in the trial setting, but they still reflect averages in a defined study population. This makes it clearer which daily-life areas and which echocardiogram measure showed the most noticeable treatment differences in these trial analyses.

Research covered in: March 2026, August 2026

A range of new approaches were reported, but the evidence remained early and exploratory.

Early-stage reports described several non-standard or next-step approaches. A first-in-human 5-person study of low-dose cardiac radiotherapy reported tolerability over 6 months, with PET uptake (a scan signal of tracer activity) tending to decrease. However, there was no improvement in key MRI measures, and short-term clinical changes varied. A phase 4 study (ACO-SWITCH) was launched to follow outcomes after switching from tafamidis to acoramidis, but results were not yet available. Other early work included a mathematical model comparing predicted reductions in an amyloid "building-block" proxy across drugs, and lab/animal or computational screens (e.g., pomegranate-derived PGG fibril disruption; food-derived compound binding predictions). These updates show what is being tested next, but they do not yet establish clinical benefit in typical wtATTR-CM care.

Research covered in: January 2026, April 2026, June 2026, August 2026

Studies linked outcomes not only to heart measures, but also to independence and fatigue.

New in September, a large tafamidis-treated cohort found frailty (lower strength and reserve) at treatment start was linked to higher mortality. Risk signals included elements such as needing help at home and reduced independence. In other cohorts in the months covered, staging systems based on blood markers continued to separate higher- and lower-risk groups in a modern (largely tafamidis-treated) era. In one multicenter cohort, a longer time from first warning signs to diagnosis was linked to higher mortality. Separately, quality-of-life work found that distress and reduced quality of life were strongly tied to fatigue and functional limitation, while several imaging measures of amyloid load were not linked to mental health outcomes in that study. This reinforces that day-to-day function and support needs can track closely with both lived burden and outcomes seen in cohorts, alongside cardiac tests.

Research covered in: August 2026, September 2026

Monitoring studies highlighted arrhythmias, slowed conduction, and the role of devices.

In the months covered, rhythm and conduction problems (heart rhythm problems or slowed electrical signals) repeatedly showed up as measurable complications in ATTR-CM cohorts. Continuous rhythm monitoring (ongoing heart-rhythm recording over time) in newly diagnosed amyloid heart disease found bradyarrhythmias (slow heart rhythms) reaching pacemaker indication and new atrial fibrillation (an irregular heart rhythm) were common, with more events in ATTR cardiomyopathy than AL in that mixed-type cohort. In a wtATTR-CM cohort followed for 1 year after starting tafamidis, average ECG conduction intervals lengthened among the 50 people analyzed. Four of the 60 originally enrolled needed permanent pacemakers and were excluded from that analysis, which may make conduction worsening look milder than it really was. Explored baseline predictors were not consistent across analyses. This supports why rhythm/conduction tracking and device decisions often remain part of follow-up even during disease-modifying therapy.

Research covered in: May 2026, September 2026